Chemomab Therapeutics Ltd ADR (CMMB) saw an uptrend of 2.35% in the recent trading with $3.48 being its most recent. The current price level -65.88% lower than the highest price of $10.20 marked by the stock while trading over the past 52-weeks, whereas it is 4.97% higher than the lowest price of $3.32 the company dropped to over past 52-weeks. The latest news story on CMMB appeared in (GlobeNewswire) under the title “Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference”.
Squeezing the time span to 30 day period shows us the stock is currently trading -27.50% below one month high and is +4.97% above of the lowest during that time. Looking into the simple moving average, Chemomab Therapeutics Ltd ADR (CMMB)’s stock stands at a SMA-50 of $4.26 while that of 5-day is reading $3.49.
Daily rise and fall of price influence many of the traders, and in order to overcome the fluctuating effect of that and to watch the stock closely, traders focus more on stock’s 200-day moving average. At various points in trading activity, investors are more likely to be making use of that measure as a strong indicator in figuring out their support and resistance levels, and CMMB’s SMA-200 as of now is $5.75.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Strong Buy by 1 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.00 for the stock.
Chemomab Therapeutics Ltd ADR Earnings – What Happened With CMMB
Coming around sales and income figures on CMMB Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Chemomab Therapeutics Ltd ADR (CMMB) last released financial results for the quarter that ended 9/30/2024, posting a surprise factor of 0.00% for net revenue.
CMMB – Chemomab Therapeutics Ltd ADR Stock Earnings Estimates
The perspective of Chemomab Therapeutics Ltd ADR (NASDAQ:CMMB)’s current quarter earnings identifies that analysts are in consensus over the estimate of -0.04 for stock’s EPS in the current quarter. Chemomab Therapeutics Ltd ADR (CMMB) last released financial results for the quarter that ended 9/30/2024, posting a surprise factor of 0.00% for net revenue. Company’s EPS for the last quarter was -0.04.
Chemomab Therapeutics Ltd ADR – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 5.17 million. CMMB does have institutional investors; and they hold 10.39% of the stock.
As on 2024-06-30, ORBIMED ADVISORS LLC was the top most holder in Chemomab Therapeutics Ltd ADR (NASDAQ:CMMB) with an ownership of 2.24 million shares of the company or 0.7834 of the stake worth $2.05 million. The filing also reveals IKARIAN CAPITAL, LLC as the second largest holder in the company with a control over 0.0746 of the outstanding shares. Its stake is worth $0.2 million for having 0.21 million shares in hand.
CITADEL ADVISORS LLC also came holding a key position in the company during the recent quarter and it now holds 0.0218 of the outstanding shares. With this there are now 15.0 institutions which have possession in CMMB’s shares.
Key Metrics for CMMB
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Chemomab Therapeutics Ltd ADR has a debt to equity ratio of 0.00.
Technical Analysis of Chemomab Therapeutics Ltd ADR (NASDAQ:CMMB) stock
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for Chemomab Therapeutics Ltd ADR (CMMB), we notice that the stock’s 20-day average volume is at 72,798 shares and 100% of short term indicators are suggesting the stock as Sell. Medium term indicators at an average of 100% are spotting the stock at Sell with its 50-day average volume of 54,825 shares. And to end, CMMB’s 100-day average volume is 42,284 shares with 100% of the long-term indicators pointing towards Sell for the stock.
